Fig. 2From: Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST studyLS mean change from baseline in monthly migraine headache days through to Month 6GMB, galcanezumab; LS, least squares; PBO, placebo; SE, standard error***p < 0.0001 (comparison between galcanezumab and placebo treatment groups)Back to article page